MLchartDataset catalogue

Landogrozumab

Term · Oncology and biomedicine · MLC-T-ONC-014710

A monoclonal antibody against myostatin (MSTN) with potential anti-cachexia activity. Upon administration, landogrozumab binds to and neutralizes the MSTN protein, thereby blocking the MSTN signalling pathway. This may help decrease muscle protein breakdown and muscle weakness and may attenuate cancer cachexia. MSTN, a member of the transforming growth factor-beta (TGF-beta) superfamily, is a negative regulator of muscle growth and development.

Table 1. Record
IdentifierMLC-T-ONC-014710
FieldOncology and biomedicine
Synonymsanti-myostatin monoclonal antibody LY2495655
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-014710",
  "term": "Landogrozumab",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody against myostatin (MSTN) with potential anti-cachexia activity. Upon administration, landogrozumab binds to and neutralizes the MSTN protein, thereby blocking the MSTN signalling pathway. This may help decrease muscle protein breakdown and muscle weakness and may attenuate cancer cachexia. MSTN, a member of the transforming growth factor-beta (TGF-beta) superfamily, is a negative regulator of muscle growth and development.",
  "synonyms": [
    "anti-myostatin monoclonal antibody LY2495655"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/landogrozumab/"
}

Record 9,904 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.